Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.43−0.02 (-3.39%)
Close on Nov 18, 2026Market cap $249.06KP/E –Yield –
Virax Biolabs operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2026 it was -$6.40M. The highest annual figure on record is -$644.54K in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$6.40M | – |
| FY2025 | Mar 31, 2025 | -$6.08M | – |
| FY2024 | Mar 31, 2024 | -$6.53M | – |
| FY2023 | Mar 31, 2023 | -$5.73M | – |
| FY2022 | Mar 31, 2022 | -$1.73M | – |
| FY2021 | Mar 31, 2021 | -$644.54K | – |
See a number that looks wrong?